138 related articles for article (PubMed ID: 29308947)
21. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
23. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Corporaal S; Smit WM; Russel MG; van der Palen J; Boot H; Legdeur MC
Neth J Med; 2006 May; 64(5):141-6. PubMed ID: 16702612
[TBL] [Abstract][Full Text] [Related]
25. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
26. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Okines AF; Langley RE; Thompson LC; Stenning SP; Stevenson L; Falk S; Seymour M; Coxon F; Middleton GW; Smith D; Evans L; Slater S; Waters J; Ford D; Hall M; Iveson TJ; Petty RD; Plummer C; Allum WH; Blazeby JM; Griffin M; Cunningham D
Ann Oncol; 2013 Mar; 24(3):702-9. PubMed ID: 23108952
[TBL] [Abstract][Full Text] [Related]
28. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
29. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma.
Patrão AS; Papaxoinis G; Kordatou Z; Weaver JM; Owen-Holt V; Alkhaffaf B; Galloway S; Mansoor W
Eur J Surg Oncol; 2019 Mar; 45(3):439-445. PubMed ID: 30786962
[TBL] [Abstract][Full Text] [Related]
31. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
32. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Voelter V; Schuhmacher C; Busch R; Peschel C; Siewert JR; Lordick F
Ann Thorac Surg; 2004 Sep; 78(3):1037-41. PubMed ID: 15337044
[TBL] [Abstract][Full Text] [Related]
33. Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors.
Larsen AC; Frøkjær JB; Fisker RV; Iyer V; Mortensen PB; Yilmaz MK; Møller B; Kristensen SR; Thorlacius-Ussing O
Thromb Res; 2015 May; 135(5):802-8. PubMed ID: 25743885
[TBL] [Abstract][Full Text] [Related]
34. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
35. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
[TBL] [Abstract][Full Text] [Related]
37. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
39. A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Wang C; Song DJ; Xu ZL; Xie SP; Hu JH
Exp Mol Med; 2017 Sep; 49(9):e383. PubMed ID: 28960212
[TBL] [Abstract][Full Text] [Related]
40. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy.
Marshall-Webb M; Bright T; Price T; Thompson SK; Watson DI
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27878904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]